Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Controlling HIV-1 Rev function.

Alan Cochrane1

  • 1Dept. of Medical Genetics and Microbiology, University of Toronto, Toronto, Ontario, M5S-1A8, Canada. alan.cochrane@utoronto.ca

Current Drug Targets. Immune, Endocrine and Metabolic Disorders
|December 8, 2004
PubMed
Summary

New HIV-1 therapies targeting Rev function offer hope against drug resistance. Combining strategies like antisense DNA and ribozymes may enhance antiviral response and prevent infection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human protein interaction networks of ancestral and variant SARS-CoV-2 in organ-specific cells and bodily fluids.

Nature communications·2025
Same author

Exploiting the Achilles' Heel of Viral RNA Processing to Develop Novel Antivirals.

Viruses·2025
Same author

Targeting protein homeostasis with small molecules as a strategy for the development of pan-coronavirus antiviral therapies.

Communications biology·2024
Same author

Putting a Kink in HIV-1 Particle Infectivity: Rocaglamide Inhibits HIV-1 Replication by Altering Gag-Genomic RNA Interaction.

Viruses·2024
Same author

Correction: An activator of G protein-coupled receptor and MEK1/2-ERK1/2 signaling inhibits HIV-1 replication by altering viral RNA processing.

PLoS pathogens·2024
Same author

Broad spectrum post-entry inhibitors of coronavirus replication: Cardiotonic steroids and monensin.

Virology·2023

Area of Science:

  • Virology
  • Molecular Biology
  • Gene Therapy

Background:

  • Current HIV-1 treatments reduce mortality but face challenges from drug-resistant strains.
  • The Human Immunodeficiency Virus type 1 (HIV-1) Rev protein is crucial for viral replication.
  • Developing alternative therapies is essential to combat resistant HIV-1 variants.

Purpose of the Study:

  • To review strategies for controlling HIV-1 replication by disrupting Rev function.
  • To explore novel therapeutic approaches for HIV-1 infection.
  • To assess the potential of combination therapies and advanced delivery systems.

Main Methods:

  • Review of various methods targeting Rev function: antisense DNA, ribozymes, decoy RNAs, transdominant proteins, and suicide vectors.
  • Analysis of the efficacy of individual and combined therapeutic strategies.
  • Examination of lentiviral-based vectors for therapeutic agent delivery.

Main Results:

  • Multiple strategies effectively disrupt HIV-1 Rev function and inhibit viral replication.
  • Combination of these strategies shows potential for a more robust antiviral response.
  • Advancements in delivery systems, such as lentiviral vectors, are progressing.

Conclusions:

  • Disrupting HIV-1 Rev function is a promising therapeutic strategy.
  • Combining multiple anti-Rev approaches could overcome drug resistance.
  • Lentiviral vector technology may enable clinical application of these novel therapies, offering protection and alternative treatment options.

Related Experiment Videos